

*Supplementary Table S1 melanoma cell lines treatment groups used for synergy assays*

Treatment	Anti-VEGFR (Lenvatinib)	Anti-MAPK (Dabrafenib)
Control	-	-
Anti-VEGFR monotherapy	10 $\mu$ M	-
low dose anti-MAPK monotherapy	-	0.0001 $\mu$ M
low dose combination therapy	10 $\mu$ M	0.0001 $\mu$ M
medium-low dose anti-MAPK monotherapy	-	0.001 $\mu$ M
medium-low dose combination therapy	10 $\mu$ M	0.001 $\mu$ M
medium-high dose anti-MAPK monotherapy	-	0.01 $\mu$ M
medium-high dose combination therapy	10 $\mu$ M	0.01 $\mu$ M
high dose anti-MAPK monotherapy	-	0.1 $\mu$ M
high dose combination therapy	10 $\mu$ M	0.1 $\mu$ M